Obinutuzumab in systemic lupus erythematosus: a real-world experience
Obinutuzumab showed favorable efficacy and safety in SLE, including severe/refractory manifestations, suggesting potential benefits for difficult-to-treat patients.
Authors
- Yinglu Wang
- Sheng Chen (ORCID: https://orcid.org/0000-0001-7428-7153)
- Shuang Ye (ORCID: https://orcid.org/0000-0002-5257-5768)
- Huihua Ding (ORCID: https://orcid.org/0000-0002-7530-8953)
- Qiong Fu (ORCID: https://orcid.org/0000-0001-5873-6422)
- Xiaodong Wang (ORCID: https://orcid.org/0000-0003-1215-6953)
- Chunmei Wu
- Yanwei Lin
- Fang Du (ORCID: https://orcid.org/0000-0003-4853-7782)
- Liangjing Lu
- S J Chen (ORCID: https://orcid.org/0009-0005-5707-8727)
Institutions
- Renji Hospital (CN)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1702550
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00